Organon & Co. (OGN) income statement
OGNNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/3013% above fair value
$13.92+0.02 (+0.14%)
Close on Nov 18, 2026Market cap $3.66BP/E 18.1Yield 2.44%
Organon & Co. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- 53.1%
- Operating margin
- –
- Net margin
- 3.5%
- Return on equity, FY2025
- 30.6%
Financial strength
- Current ratio
- 2.02
- Debt to equity
- 7.17
- Debt to assets
- 63.8%
- Cash to current liabilities
- 54.9%
Valuation
- P/E ratio
- 18.1
- Price to sales
- 0.60
- Price to book
- 3.06
- Dividend yield
- 2.44%
See a number that looks wrong?